Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 02/11/20
Coherus BioSciences Offers Compelling Long-Term Gain Opportunities With Low RiskSeeking Alpha • 02/04/20
Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United StatesGlobeNewsWire • 01/13/20
Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 01/07/20
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/06/19
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/02/19
Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped TodayThe Motley Fool • 07/08/19
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/10/19
Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/19